登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，2月27日，Convalescent plasma as a potential therapy for COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-02-28

  • Convalescent plasma as a potential therapy for COVID-19

    Long Chen, Jing Xiong, Lei Bao, Yuan Shi

    Published:February 27, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30141-9

    The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which originated in Wuhan, China, has become a major concern all over the world. The pneumonia induced by the SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). By Feb 22, 2020, this virus has affected more than 77?700 people worldwide and caused more than 2300 deaths. To date, no specific treatment has been proven to be effective for SARS-CoV-2 infection. Apart from supportive care, such as oxygen supply in mild cases and extracorporeal membrane oxygenation for the critically ill patients, specific drugs for this disease are still being researched. In the USA, the first patient infected with SARS-CoV-2 was treated by supportive care and intravenous remdesivir, before the patient recovered and was discharged.1 However, randomised clinical trials are needed to evaluate the safety and efficacy of remdesivir in the treatment of COVID-19.

  • 原文来源：https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30141-9/fulltext
89浏览量
原文链接
相关报告

  • 《JAMA，3月27日，Convalescent Plasma to Treat COVID-19 Possibilities and Challenges》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-28
    • Convalescent Plasma to Treat COVID-19 Possibilities and Challenges John D. Roback, MD, PhD1; Jeannette Guarner, MD2 Author Affiliations Article Information JAMA. Published online March 27, 2020. doi:10.1001/jama.2020.4940 In this issue of JAMA, Shen et al report findings from a preliminary study of 5 severely ill patients with coronavirus disease 2019 (COVID-19) who were treated in the Shenzhen Third People's Hospital, China, using plasma from recovered individuals.1 All patients had severe respiratory failure and were receiving mechanical ventilation; 1 needed extracorporeal membrane oxygenation (ECMO) and 2 had bacterial and/or fungal pneumonia. Four patients without coexisting diseases received convalescent plasma around hospital day 20, and a patient with hypertension and mitral valve insufficiency received the plasma transfusion at day 10. The donor plasma had demonstrable IgG and IgM anti–SARS-CoV-19 antibodies and neutralized the virus in in vitro cultures.
    114浏览量
    原文链接

  • 《LANCET，2月27日，COVID-19: preparing for superspreader potential among Umrah pilgrims to Saudi Arabia》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-28
    • COVID-19: preparing for superspreader potential among Umrah pilgrims to Saudi Arabia Shahul H Ebrahim Ziad A Memish Published:February 27, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30466-9 The ongoing coronavirus disease 2019 (COVID-19) outbreak is a Public Health Emergency of International Concern (PHEIC), and the emergence of new epicentres of spread, such as South Korea and Iran, besides Wuhan, China, should draw attention to potential superspreader events.1 Of concern is the continuous Umrah pilgrimage to Saudi Arabia by Muslim pilgrims from more than 180 countries. In addition to the non-pilgrim air traffic (39 million people in 2018), Saudi Arabia received 7·5 million Umrah visa holders in 2019 (appendix).
    88浏览量
    原文链接